Aphria Announces Production Starts At Rapid Dose Therapeutics Inc.

Aphria Inc. (TSX: APHA and NYSE: APHA) today announced it has established an agreement with Rapid Dose Therapeutics Inc. that grants the Company with exclusive global preferred rights to license, manufacture, distribute and sell RDT's QuickStrip™ innovative, proprietary delivery technology for both medical and adult-use cannabis market.

The Company intends to begin production of oral thin strips at its production facilities in Leamington, Ontario in 2019.

"Aphria is excited to revolutionize the way patients and consumers integrate cannabis into their lives and to bring QuickStrip™ technology – a product unlike any other – to the cannabis market," said Jakob Ripshtein, President of Aphria. "This agreement with RDT further demonstrates Aphria's commitment to bringing advanced products and innovations that will fit the needs of every consumer. Further, the QuickStrip™ technology will help ease concerns surrounding consumption by providing a product that delivers a consistent and precise dosage form."

RDT's proprietary QuickStrip™ technology is a Quick, Convenient, Precise, Discreet™ oral fast-dissolving drug delivery system that offers a smoke-free choice to consumers.

Aphria is a shareholder of RDT, having acquired 7,200,000 shares in a non-brokered private placement completed in August 2018 at a price of $0.75 per share for total gross proceeds of $5,400,000, representing approximately a 9.7% interest in the company. 

We Have A Good Thing Growing.

About Aphria
Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company's portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders' multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.For more information, visit: aphria.ca

Source Click Link Below

https://technical420.com/cannabis-article/aphria-establishes-exclusive-agreement-rapid-dose-therapeutics-bring-innovative

From The StockHouse Bull Board- Vic Opens AGM In German

Aphria AGM

Attended the AGM and agree with most of the comments posted. Would definitely reinforce that at some point a deal or "deals" will be made with one or more  multinational partners. My sense is that at least one of the potential partners would preferably be from the pharma sector. Big, big pockets there with worldwide exposure. Bayer as an example. Interesting that Vic started the meeting speaking in German.

Definitely looking forward to mid 2019 when Apha rolling with 20000 kg per month and the lowest cost producer. Vic focussed quite a bit about building a long term sustainable business from the ground up with international influence. Also Vic restated his conviction that eventually the US would be the " home run" in terms of business.

In terms of share price, Vic said don't focus on the daily fluctuations. Felt that listing in the US would not only aid in exposure but also aid in less volatility in the stock price.
All in all, a good meeting.

Next:

Tom Looney Joining board of directors?

I believe the reason that Aphria is top on the interest list for possible takeover by one of the huge American companies is due to the fact that they are seen as one of the top players in the MJ sector.  And yet they have a much lower market cap than the other potential takeover targets like Aurora and Tilray.

Next:

"Everyone has probably heard the rumour that (those two companies) are sniffing around"....classic misdirection and I think it was meant for Christina Pellegrino. 

 He, as Monteviale was mentioning was directing his attention to that portion of the room.  

I'm pretty certain he wants nothing to do with them...however I'm less certain about BAYER. 
I think that would be a world class partnership and he does spend a LOT of time in Germany. 

 I am most hopeful that we get a pharma deal done first and then a JV or minor stake investment by Altria.  That would be a perfect world.  

I understand that there can be a negative view on some companies but in the end the entire Pharma space has it's warts.  

There is no better partner than pharma if you are looking to maximize your return on investment.  

That's why I'm here.  

With an investment from pharma the entire marketplace would be affected in a positive way. 

 It would be a much bigger impetus for the industry. 
Atheena

Next:

I very much appreciate all the posts info about the agm

And I am confident in APHA 's future and the team that is leading us , it is most reassuring to hear vic address the sp volatility and basically say ignore it because we got this under control that is what I need to hear from my quarterback and that’s how you become the GOAT!

Next:

Happy Thoughts

With Ripshtein as APHA's president I believe that the Directors of Diageo are FAR more likely to invest in APHA as they value Jakob and Tom opinions and expertise. 

I am curious if proceeds from the three-tranche $2B Euro bonds 

DEO recently issued are being considered for such a stake.

Read more at http://www.stockhouse.com/companies/bullboard?symbol=t.aph&postid=28919847#iLqtcUvLgZikbK2s.99